propensity for amyloid fibril formation, pharmaceutical glucagon [e.g. GlucaGen ® HypoKit ® (Novo Nordisk, Princeton, NJ) or Glucagon™ (Eli Lilly and Company, Indianapolis, IN)] is currently supplied as a powder to be dissolved in supplied water immediately before use. Despite the +5 charge of glucagon at acidic pH in the resulting solution, the dissolved peptide gradually aggregates and eventually forms amyloid-like fibrils, which share the intermolecular cross β-pleated sheet architecture with amyloid protein deposits found in histological samples from amyloidosis patients. 15 
Amyloid-Disease-Related and/or Functional Structures
The word amyloid is usually associated with degenerative diseases such as type 2 diabetes mellitus, Alzheimer's disease, 16 and prion diseases. 17, 18 Amyloid formation can result in loss of natural protein function, as well as toxic gain-of-function. 19 However, pre-fibrillar oligomeric structures of many proteins appear to have a higher toxicity than large amyloid aggregates, 20 possibly because of larger surface-to-mass ratios. 21 It has been suggested that the formation of large amyloid-like deposits may, at least in some cases, represent an active mechanism by which cells can protect themselves against smaller, more cytotoxic aggregates. 22, 23 Indeed, amyloid structures may not be generally cytotoxic, as an increasing number of functional amyloid structures are being reported, involved in biofilm formation, melanin anchoring, reduction of interfacial tension, and coating of spores. 24, 25 It has been proposed that glucagon could be stored in the α-helical trimeric form inside the pancreatic α-cells, 6 possibly stabilized by divalent cations such as Zn 2+ as seen for insulin. 29 However, recent studies suggest that glucagon and several other peptide and protein hormones may be stored as functional amyloid-like structures inside pituitary secretory granules. 30 In line with this, these hormones exhibit a high propensity to form amyloid of relatively low stability allowing them to revert to functional state upon secretion. 31 However, several studies indicate that the aggregates formed by glucagon can be particularly toxic, 32 exceeding that of other peptide hormones and the amyloid-β-peptides (Aβ), 30 which appears inconsistent with a functional role of glucagon amyloid. However, in contrast to the single native protein fold, several amyloid-folds can be generated from the same sequence, [33] [34] [35] [36] and recent studies indicate that toxicity depends greatly on the structure of the protein aggregate. 37, 38 This means that toxicity could arise from a particularly toxic type of glucagon fibril formed under the given conditions. We have recently demonstrated that glucagon is able to form at least five different types of amyloid-like fibrils that can be propagated by seeding in a strain-specific manner, 12, 28, 39, 40 as previously known for prions. 41, 42 Each fibril type can be identified from a unique combination of specific characteristics, including thioflavin T (ThT) staining, circular dichroism (CD) spectrum fingerprints, thermostability and morphology in electron microscopy (EM) (see Figure 2 and Table 1 ), suggesting that the fibrils differ at the level of molecular packing of glucagon. 39, 43, 44 Figure 1. Conformational states of glucagon ranging from α-helical crystals and trimers, α-helical or random-coil monomers to several types of β-sheet-rich amyloid-like fibrillar states (see text for details). Picture of glucagon crystals, 4 coordinates for trimer, and α-helical and random coil glucagon taken from the pdb data base entries 1gcn, 6 1KX6, 26 and 1NAU. 27 Electron microscopy image gallery of glucagon fibrils with 50-nm scale bar.
(T m app <32 °C), compared to type B agitated fibrils (T m app = 55 °C) that form at low glucagon concentrations. 39 In contrast to the +5 predicted for monomeric glucagon at pH 2.5, the net charge of glucagon in type B agitated fibrils appears to be zero. 46 Consequently, the stability of type B agitated fibrils is highly dependent on pH, and they can be dissociated instantly by decreasing the pH to 1.1. 39 In contrast, type S fibrils are very stable in acid, but T m app is highly dependent on salts in the solution increasing with 22 °C for every tenfold increase in salt concentration ( Figure 2C ). Divalent sulfate anions are particularly stabilizing to type S fibrils, and addition of only 1 mM Na 2 SO 4 (7:1 ratio glucagon at 0.5g/liter or 0.144 mM) gives them a selective growth advantage
All Types of Glucagon Fibrils Form Reversibly and Show Differences in Stability
The CD spectrum of different types of glucagon fibrils exhibit unique fingerprint features that distinguish them (Figure 2A) , even though the secondary structure information is not straightforward to interpret. 12, 39 The stability of different fibrils can be compared by monitoring the changes in CD spectrum during gradual temperature ramping giving reproducible thermal melting mid-points (T m app ) for most types of fibrils ( Figure 2B ). Type A fibrils that form at high glucagon concentrations represent the least stable fibril type characterized so far, with a low melting midpoint 45 (B) Stability of fibrils can be estimated for comparative purposes by monitoring changes in CD during temperature ramping at constant speed (90 °C/h, 0.025 g/liter sonicated fibrils, 25 mM glycine/HCl pH 2.7). 39 (C) Stability of type S fibrils is highly dependent on salt concentrations and SO 4 2-anions are particularly stabilizing to the fibrils. 40 (D) Comparison of fibril morphology of different types of glucagon fibrils as viewed in electron microscopy. Scale bar is 50 nm. over other fibril types. 40 This suggests that the positive charges of glucagon become incorporated into type S fibrils, shielded by the interaction with counter ions from the solution. 40, 43 Consequently, type S fibrils dissociate rapidly when pH is increased beyond neutral, most likely because of the electrostatic repulsion between the negative charges of the SO 4 2-and the deprotonated N-terminus and the three asparagine residues. 40 On the other hand, type B fibrils remain intact and also form de novo at pH 9.5.
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Intrinsic Tryptophan Fluorescence Can Be Used to Monitor the Formation of Glucagon Fibrils
A variety of methods have been used to monitor the aggregation of proteins into fibrils, ranging from simple sample turbidity readings to X-ray diffraction and calorimetry. 47 In situ ThT fluorescence 48 is a frequently used method that allows high-throughput monitoring of amyloid fibril formation kinetics. However, because some types of fibrils stain very poorly with this dye, ThT emission cannot be used as a general quantitative measure for the extent of fibril formation. 39 Glucagon contains a single tryptophan (Trp) residue, 49 a particularly useful internal spectroscopic probes whose fluorescence spectrum reports on the local environment of the side chain. 50 Fibril formation changes the emission spectrum of glucagon Trp-25, in most cases a dramatic blue-shift in emission maximum from around 352 nm for monomer to as low as 318 nm for type B fibrils is observed, 39 indicating embedding of the side-chain in a hydrophobic environment. Such spectral changes can be used to quantify the degree of glucagon fibril formation, even for fibril types that do not stain with ThT. Moreover, the fluorescence spectrum also contains information about local structure and solvent accessibility of Trp, 43 which in combination with other techniques played a key role in the discovery of different types of fibrils and the mechanisms by which they form.
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Fibrils Grow Exponentially from Unfavorable Thermodynamic Nuclei
The elongated shape of fibrils implies that they grow linearly by addition of molecules to their ends. 51, 52 Exponential growth of fibrils can be achieved via secondary pathways, such as branching, breaking or heterogeneous nucleation (catalysis of nucleation by existing fibrils), which result in a continuous increase of the number of fibril ends that can accept monomers at a rate proportional to fibril mass present at any given time. 53 Formation of individual types of glucagon fibrils can be studied by adjusting solution conditions to favor growth of that particular type fibril ( Table 1) , such as relatively low glucagon concentrations together with agitation for type B agitated (see Figure 3 ). Quantitative seeding assays (QSA), where a monomeric solution is seeded with a dilution series of preformed fibrils, can be used to reveal kinetic properties of the mechanism by which they were formed. The linear correlation between the logarithm of the amount of seeds added and the lag-time or threshold time (t threshold ) clearly demonstrates that the fibrils grow exponentially even through the period where the amount of fibrils is below the detection limits ( Figure 3B ). The rate of exponential growth under the given conditions, in this case a doubling time of 38.5 minutes, can be accurately calculated from the slope of the curve. The t threshold for the unseeded experiment can be used to estimate nucleation rates. Although nucleation in principle occurs throughout the experiment, the exponential growth of fibrils from early nucleation events contribute to the majority of the fibrils formed, minimizing the effect of later nucleation events. 53 Notably, the lag-time is highly reproducible even for the unseeded experiment, 39 which suggests that glucagon fibril nucleation is not a single stochastic event, but can be considered as an unfavorable thermodynamic equilibrium between monomers (0.5 g/liter) and type B aggregated nuclei/seeds (<9 × 10 -8 g/liter) at the given conditions. It is often stated that amyloid formation proceeds via a complex multistep mechanism involving several intermediate states. 56 However, several studies designed to detect intermediate states during formation of glucagon fibrils using size exclusion chromatography, 32 fast field fractionation, 57 dynamic light scattering, 12 nuclear magnetic resonance (NMR) 58 and small angle X-ray scattering, 54 did not detect accumulation of any oligomeric intermediate species other than the aforementioned α-helical trimers. Thus it appears that complexity arises not from obligatory intermediates, but from the competition between multiple aggregation pathways. 28, 34, 45 
Different Fibril Types Form via Distinct Pathways
Structural investigations of the individual glucagon fibril types can reveal the secondary pathway by which they achieve exponential growth. Time-lapse total internal reflection fluorescence microscopy demonstrates directly that type B unagitated fibrils grow via branching under conditions without agitation 55 ( Figure 4A) . The branching generates new fibril ends that can accept monomers resulting in slow exponential growth. 53 Agitation or stirring has been reported to accelerate fibril formation of a number of proteins, including insulin, 59 prions, 60 Aβ, 36 and glucagon. 39 Electron microscopy pictures demonstrate progressive shortening of type B agitated glucagon fibrils formed under agitated conditions (Figure 4B) , suggesting that this catalyzes, breaking to create more free fibril ends. 18, 62 The CD spectrum of fibrils formed with and without agitation is very similar (Figure 2A) , but their morphology in EM images is remarkably different (Figure 2D ): Type B unagitated fibrils are twisted and show branching, whereas type B agitated form parallel pairs, suggesting that differences in packing of protofilaments is important for the ability of fibrils to branch and break, respectively. Remarkably, the Aβ 1-40 peptide forms similar self-propagating "quiescent" and "agitated" fibrils, which share the twisted and non-twisted morphologies of type B unagitated and B agitated glucagon fibrils, respectively. 36 According to solid-state NMR the packing of the Aβ in the two fibrils types is similar, but quiescent fibrils have a triangular cross-section with a narrow central cavity created by three protofilaments, while the agitated only consist of two protofilaments. 63 Quiescent and agitated forms of insulin fibrils with different optical properties have recently been reported. 64 Moreover, the intriguing "stirred" and "rotated" types of human prion fibrils 65 suggest that different modes of agitation may specifically enhance the secondary pathways for particular fibril types, giving these selective growth advantage over other types of fibrils.
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Figure 4. The secondary pathways leading to exponential growth of glucagon fibrils in 50 mM glycine/HCl buffer at pH 2.5. (A) Total internal reflection fluorescence microscopy image from a time series demonstrating that branching of type B unagitated increases the number of fibril ends under unagitated conditions. 55 (B) Electron microscopy image from a time series demonstrating progressively shorter fibrils, indicating continuous increase in number of fibril ends due to breaking of type B agitated fibrils under agitated conditions. 39 (C) Time-courses of Trp fluorescence during seeding of 1 g/liter glucagon with 5-fold dilution series, starting at 1%, of type B agitated ( • ) or type D (°) shows different significant difference both spectrum and curve shape. At low seeding fractions of type Bagitated significant amounts of type A fibrils form transiently, resulting in a lowered F330nm/F355nm fluorescence ratio at low seeding fractions. 39 (D) Effect of surface properties on glucagon fibril formation kinetics of glucagon at variable concentrations in 50 mM glycine/HCl pH 2.5 with 3-second agitation every 10 minutes, using either polyethylene oxide nonbinding surface (NBS™, Corning, Lowell, MA) or standard polystyrene (PS Nunc) plates. Lag times and elongation rates (signifying the maximum slope of the growth curve) were determined using the previously described formula.
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Growth rate of type B glucagon fibrils is highest between 0.3 and 0.6 g/liter 39 and concentrations above this significantly inhibit their formation, possibly due to the formation of α-helical trimers. 12 In contrast, the relatively unstable type A fibrils grow well even at concentrations above 8 g/liter where α-helical trimers are abundant. 12, 39 When growth of type A fibrils reaches equilibrium (i.e., where elongation and dissociation rates are equal) the remaining concentration of free glucagon is still sufficient, and now low enough, to allow the growth of type B unagitated fibrils. 45 As the more stable type B fibrils consume the remaining monomers, the dissociation rate of the unstable type A fibrils becomes larger than the elongation rate, leading to a net conversion from type A to B unagitated fibrils. Thus, type A fibrils act as an off-pathway reservoir that lowers glucagon concentration sufficiently to allow formation of type B unagitated fibrils. 45 Comparison between the development of Trp emission spectrum during seeding with type B agitated or type D fibrils demonstrates propagation of the spectrum of the seeding parent fibrils (Figure 4C) , and reveal that the two form via distinct pathways. 39 Thus, one can think of the different fibril types as microbe species that grow exponentially by consuming the media nutrients (glucagon monomers) in competition with each other, 28 with the important addendum that fibril nuclei can materialize spontaneously. Accordingly, fibrils types that are incapable of exponential growth and nucleate slowly never reach our detection limits before they are outcompeted by types that do grow exponentially.
Studies on the formation of insulin and Aβ fibrils have demonstrated that the properties of surfaces that contact protein solutions can have a tremendous impact on both the rate of fibril formation and the type of fibrils formed. 35, 38, 66 Changing the surface properties of microtiter plates used for the glucagon fibril formation assay from untreated polystyrene to non-binding polyethylene oxide increases lag times, but also changes the shape of growth curves, suggesting that binding to surfaces may catalyze both growth and/or nucleation of specific types of glucagon fibrils (Figure 4D ).
Strategies for Controlling Fibril Formation
Delivery of both insulin and glucagon in an automated closed-loop system is currently being pursued as a method of improving quality of life in patients with type 1 diabetes. 61, 67, 69 Such systems require stable liquid formulation where formation of fibrils is minimized due to potential clogging of infusion catheters in addition to potential toxicity of fibrils formed. Knowledge of the mechanisms that lead to protein fibril formation is an important prerequisite to the design of strategies to prevent it. In principle, prevention of nucleation, elongation or secondary pathways should all significantly hamper fibril formation. Having non-binding surfaces contact glucagon solutions is important (Figure 4-D) ; however, a single crack in the surface of a tube could catalyze fibril nucleation and would be enough to start exponential growth of fibrils.
The effects of various additives on growth and nucleation rates for different fibril types can be tested with QSA (Figure 3) . Designed peptide inhibitors of amyloid structures have been tested for Aβ, 70, 71 and there is evidence that this strategy might have value because purity of glucagon has great impact on fibril forming kinetics 4 ; fibrils grow much faster from highly purified pharmaceutical-grade glucagon compared to samples containing several solid-state synthesis-derived impurities. 72 Moreover, addition of 1% oxidized glucagon dramatically decreases growth rate of fibrils, and introduces variability in the otherwise highly reproducible lag-time for fibril formation, 61 suggesting that glucagon analogs can interfere with fibril formation by competing with or blocking unmodified glucagon adsorption at the ends of fibrils. However, the ability of glucagon to form a multitude of different aggregates means that strategies to design inhibitors based on the structure of a particular fibril type could fail, because glucagon simply forms other types of fibril structures immune to this register poisoning. Therefore a strategy of stabilizing monomeric form, preventing it from interacting with other molecules, appears to be a much more attractive method for inhibition of fibril formation in general.
α, β, and g cyclodextrins (CyD) are cyclic sugars consisting of 5, 6 or 7 α-D-glucosyl units, respectively, which have found extensive use as excipients in pharmaceutical formulations due to the ability of their lipophilic inner cores to bind and stabilize a variety of drug molecules. 73 The core of β-CyD has an appropriate size to fit aromatic side chains, 74 and a small change in emission spectrum indicates that β-CyDs also bind Trp-25 of glucagon, which is not observed α-CyDs (Figure 5A ). Because of their low solubility in water, β-CyDs are often modified with various chemical groups on the "edge"-hydroxyls to increase solubility. 75 According to Trp-based kinetics, addition of hydroxypropyl-β-CyD (HP-βCyD) results in a significant increase in lag-times for the formation of both type B agitated and type S fibrils (Figure 5B ), whereas addition of 12 mM methyl-β-CyD (M-βCyD) is able to block formation of type B agitated fibrils completely, even though conditions were designed to favor their formation ( Figure 5C , Table 1 ). In contrast, lactose, used as excipient in the current formulation of glucagon for injection, only results in a slightly increased lag-time of fibril formation (Figure 5B, insert) . The similar binding curves of HP-and M-βCyD to Trp-25, but dissimilar effects on fibril formation suggests that M-βCyD binds multiple aromatic side-chains on glucagon, possibly the phenylalanine-6 and/or tyrosine-10 found to be important for fibril formation. 72 Whereas HP-β-CyD is approved by the Food and Drug Administration as safe for use as an excipient in parenteral drugs, 76 the M-βCyD is not approved for injection because of its disruptive ability to extract cholesterol from cell membranes leading to hemolysis. 73, 77 However, M-βCyD is approved for oral and nasal administration and has been tested as an effective excipient in glucagon formulated nasal administration. 78 Despite low stabilizing effects of g-CyDs on human growth hormone compared to α and β-CyDs, 74 addition of g-CyDs have been reported to have an inhibitory effect on glucagon fibril formation comparable to or exceeding β-CyDs. 79 Moreover, g-CyDs also appear to improve the chemical stability of solid-state glucagon compared to lactose, 80 decreasing the oxidation and spontaneous decomposition of the dried peptide. Novel variants of water-soluble β-CyD and g-CyDs are 
continuously emerging, 73 and it is possible that some of the newer variants may have just the right ability to stabilize glucagon both chemically and physically, while still being safe for parenteral use.
Fibrillar Glucagon as Pharmaceutical Substance?
Even if fibril formulation of glucagon can be suppressed using the aforementioned strategies, the chemical stability of aqueous peptide solutions will always be limited because of the natural decomposition of peptides due to hydrolysis, oxidation, and deamidation, etc. These processes are expected to proceed significantly faster in monomeric states than in the less accessible stable amyloid states. 39 If glucagon is indeed stored as functional amyloid inside the α-cells, 30 it may be possible to mimic this in pharmaceutical formulation, perhaps by copying the natural structure using a seed propagation. With the large variety of possible fibrillar packings available to glucagon, it is possible that other fibril types may actually be more suitable for pharmaceutical formulations if practical challenges of the potentially increased viscosity leading to clogging of tubing can be overcome. The ideal candidate fibril type would naturally be non-toxic when injected, have high solubility and stability under formulation conditions, but still dissociate readily under physiological conditions to allow rapid activity. The most likely candidate of the currently described fibril types is probably type S fibrils. These fibrils can be formed reliably and reproducibly and are very soluble and stable under acidic conditions supplemented with sulfate. However, upon removal of sulfate or change in pH to neutral, such as found in blood, the fibrils dissociate instantly. 40 Future experiments are naturally required to test the safety of different types of glucagon fibrils.
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